Want to see SE:ACTI full AI Analyst Report?
Active Biotech AB (ACTI) Drug Pipeline
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Laquinimod | Eye Diseases | Phase I | Completed | A Study of Laquinimod Eye-drops in Healthy Participants | Dec 06, 2021 | ― |
| Tasquinimod | Prostate Cancer | Phase III | Completed | A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer | Nov 01, 2010 | ― |
| Abr-215050, Tasquinimod | Prostate Cancer | Phase II | Completed | Efficacy Study of ABR-215050 to Treat Prostate Cancer | Nov 15, 2007 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Laquinimod | Phase I | Eye Diseases | Completed | A Study of Laquinimod Eye-drops in Healthy Participants | Dec 06, 2021 | ― |
| Tasquinimod | Phase III | Prostate Cancer | Completed | A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer | Nov 01, 2010 | ― |
| Abr-215050, Tasquinimod | Phase II | Prostate Cancer | Completed | Efficacy Study of ABR-215050 to Treat Prostate Cancer | Nov 15, 2007 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Active Biotech AB (SE:ACTI) have in its pipeline
Active Biotech AB SE:ACTI is currently developing the following drugs: Laquinimod, Tasquinimod, Abr-215050, Tasquinimod. These drug candidates are in various stages of clinical development as the company works toward FDA approval.